Literature DB >> 678388

Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism.

J G Kelly, D G McDevitt.   

Abstract

1. The possibility that thyroid disease might result in alterations in the plasma proteins binding of drugs has been investigated by studying the binding of propranolol and isoprenaline in patients with hyperthyroidism and hypothyroidism. 2. Plasma protein binding of propranolol and isoprenaline has been measured in seven hyperthyroid patients and ten hypothyroid patients. Plasma binding was estimated by equilibrium dialysis at 37 degree C using triatiated propranolol and isoprenaline, both when the patients had thyroid dysfunction and again when they were euthyroid. 3. In the hyperthyroid group, mean propranolol binding varied from 86 +/- 1.7% when hyperthyroid to 88.4 +/- 0.8% when euthyroid. The comparable isoprenaline figures were 65.1 +/- 3.2% and 68.1 +/- 1.4% respectively. Neither difference was significant. 4. Isoprenaline binding was significantly lower (64.3 +/- 1.6%) when patients were hypothyroid than when they became euthyroid (68.8 +/- 1.2%). Propranolol binding was not altered by hypothyroidism. 5. It is concluded that clinically important alterations in free drug concentrations of propranolol or isoprenaline do not occur in hyperthyroidism or hypothyroidism.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 678388      PMCID: PMC1429399          DOI: 10.1111/j.1365-2125.1978.tb00836.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  The use of kanamycin in equilibrium dialysis at 37 degrees.

Authors:  K F Ilett; I E Hughes; L B Jellett
Journal:  J Pharm Pharmacol       Date:  1975-11       Impact factor: 3.765

2.  Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis [proceedings].

Authors:  R A Branch; D M Kornhauser; D G Shand; G R Wilkinson; A J Wood
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

3.  Plasma protein binding of propranolol in disease states [proceedings].

Authors:  O Borga; I Odar-Cederlöf; K M Piafsky; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

4.  The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors:  G H Evans; A S Nies; D G Shand
Journal:  J Pharmacol Exp Ther       Date:  1973-07       Impact factor: 4.030

5.  Influence of disease on binding of drugs to plasma proteins.

Authors:  M M Reidenberg; M Affrime
Journal:  Ann N Y Acad Sci       Date:  1973-11-26       Impact factor: 5.691

6.  Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

Authors:  G H Evans; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

7.  Studies of the reputed augmentation of the cardiovascular effects of catecholamines in patients with spontaneous hyperthyroidism.

Authors:  V S Aoki; W R Wilson; E O Theilen
Journal:  J Pharmacol Exp Ther       Date:  1972-05       Impact factor: 4.030

8.  Binding of catecholamines to human serum albumin.

Authors:  A Danon; J D Sapira
Journal:  J Pharmacol Exp Ther       Date:  1972-08       Impact factor: 4.030

  8 in total
  11 in total

Review 1.  Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).

Authors:  R Zini; P Riant; J Barré; J P Tillement
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor blocking drugs in thyroid disease.

Authors:  J Feely
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

5.  Altered plasma protein binding of drugs in thyroid disease.

Authors:  J Feely; I H Stevenson; J Crooks
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

6.  Serum protein binding of propylthiouracil.

Authors:  J P Kampmann; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

7.  Left ventricular function in hypothyroidism. Responses to exercise and beta adrenoceptor blockade.

Authors:  J C Forfar; A L Muir; A D Toft
Journal:  Br Heart J       Date:  1982-09

8.  The influence of age, smoking and hyperthyroidism on plasma propranolol steady state concentration.

Authors:  J Feely; J Crooks; I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

9.  Plasma propranolol steady state concentrations in thyroid disorders.

Authors:  J Feely; J Crooks; I H Stevenson
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

10.  Pharmacokinetics and pharmacodynamics of propranolol stereoisomers in hyperthyroid patients.

Authors:  K Tawara; K Kawashima; H Ishikawa; K Yamamoto; K Saito; A Ebihara; S Yoshida
Journal:  Eur J Clin Pharmacol       Date:  1981-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.